Dow Jones 10492.82 +22.23 8:36 am PST, April 05, 2004  NASDAQ 2060.41 +3.24 For info, visit access.smallcapnetwork.com S & P 500 1143.20 +1.39 To be removed, please click here Russell 2000 602.33 -1.12 VOLUME 04: ISSUE 25  Feature: BioCurex - Firing on ALL cylinders. As dawn broke, Monday, BioCurex (OTCBB: BOCX) stormed out of the gate, trading north of $1.40 a share. The shares closed at 54 cents, Friday. In our original Trading Alert late last year, we brought the shares to the SmallCap readership at 17 cents. That's more than an 800 percent gain in six months. Salient points: The company released it's 2004 strategic plan, Friday (release attached) Extremely impressive initial Lung Cancer detection results with the company's Serum-RECAF blood test were released Monday morning (release attached) Management has been working diligently--and successfully-- to tell its story to potential investors and partners With the adoption last week of the naked short selling rule, the stock has likely been the beneficial recipient of some short covering. Recent results noted and others to come continuing to validate the company's technology and potential. Needless to say, the shares have moved further and faster than anyone anticipated. While we believe that there could be some pullback from these levels, there is little doubt that over the long term, the commercialization of BioCurex's diagnostic technology could yield huge results.  As today's action still only market caps the company at $25 million, commercialization of its technology within cancer test markets --that are worth billions of dollars a year--still make the shares a compelling long-term buy. That said, for SmallCap readers that followed our initial Trading Alert, an extremely large gain has been noted. One certainly couldn't be faulted with taking at least a partial trading profit. A decent core position and adding to holdings strategically would be the best play from here. Investors will want to own this stock for further announcements and potential partner and alliance deals to come. We will have a more detailed assessment of the company's activities in the near future, but for now, suffice it to say that both the acceptance of the technology and potential developments to come are extremely encouraging. Quiet no more... While the shares and the company have been relatively quiet over the last few months, there is little doubt that that has changed. With results regarding the company's Histo-RECAF biopsy tests in Japan and France to be released soon, and talks with potential licensees and strategic partners ongoing, BioCurex has moved onto investor radar screens, not with a whimper but a bang. And we believe that the fortunes of this unique company will continue to increase over the coming weeks and months. The commercialization of BioCurex's technology is merely the first step in the long-term development of more cancer therapies and treatments to come. Patience has been an extremely worthwhile strategy for investors of this company even though, until recently, there hasn't been much to publicly disseminate. As we said, that's obviously changed and as more news comes out, we will keep you apprised. For now, enjoy the ride and know that we believe the best is yet to come. Take a few moments to read the accompanying press releases. We think you'll agree there is much afoot at BioCurex.   Press release #1 BioCurex: Aggressively Moves Ahead with 2004 Strategic Plan Friday April 2, 4:56 pm ET RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--April 2, 2004--Dr. Ricardo Moro, President and CEO, BioCurex Inc. (OTCBB:BOCX - News) released the company's corporate forecast for 2004. The core of BioCurex's technology is the discovery and subsequent patenting related to a molecule found on cancer cells that is practically absent from normal cells or benign tumor cells. The molecule serves as a cancer "marker" that is found on the surface as well as inside a cancer cell. The company has called it RECAF(TM). Initially, the company developed and reported on a tissue test (Histo-RECAF) and received FDA recognition for its ability to detect cancer cells. The product development and subsequent approval provided early proof of concept for its technology. In 2003, the company developed and tested a blood test for RECAF(TM) that is unparalleled in its ability to detect many types of cancer with 90% sensitivity and 95% specificity in the cancers the company has studied to date. No other company can make this claim; BioCurex has superb technology. The types of malignancies in which the assay has been shown to work cover 60% of all types of cancers. Therefore, it is reasonable to suggest that the Serum-RECAF(TM) test could find use in general screening of many populations, enabling an early diagnosis of any of these cancers. Early detection is the key to providing improved prognosis for all cancer patients. Further, the test should find early use in the monitoring of cancer patients who have received treatment, but who must be regularly evaluated for any recurrence of cancer. Strategic Plan for 2004     * Results from Japanese and French tests for Histo-RECAF biopsy test expected shortly     * Continued testing of various cancer types with the company's RECAF technology with timely reporting of results     * Discussions currently underway for licensing of BioCurex technologies with strategic alliance partners     * Expansion of specific non-disclosure agreements with well-established potential licensees for the exchange of data.     * Intent to finalize -- in 2004 -- a major licensing deal as well as deals with smaller companies for niche applications of the company's unique technology.     * Directors and Officers will continue taking shares or options in lieu of salary to maintain cash for research and development.     * Realization of further patents for over 40 claims granted or pending in over 20 countries. (A RECAF patent for China was granted in late 2003) Other patents previously secured in the United States, Australia and Russia.     * Continued research and development for enhancement of the company's products.     * Planned use of the facilities of large licensees to acquire FDA approval where applicable. Allows their well established pipelines to expedite the process. Approvals for diagnostic tests take place in short time frames     * Once RECAF has developed licensing relationships for its proprietary diagnostic tests, more efficacies will be developed for cancer therapy and management.     * Minimal competition identified due to proprietary nature of BioCurex's technology as well as patent protections in place.  BioCurex has worked diligently and progressively to develop, test and improve its technology. The company has demonstrated unique ability to detect various cancers with a blood test -- something which has not been possible to date in the world community. In a number of cases, BioCurex has been approached directly by well-established medical testing companies to engage in substantive strategic alliance and/or licensing discussions. The company expects that trend to continue and increase as its products gain more exposure within the medical and oncological communities. To read more regarding the state of the company, kindly visit its Web site at www.biocurex.com. Contact: BioCurex Inc., Rancho Santa Margarita Dr. Ricardo Moro, 866-884-8669 Fax: 866-437-2277   Press release #2 BioCurex Blood Test Detects 90% of Leading Cancer Killer Monday April 5, 8:30 am ET RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--April 5, 2004--BioCurex Inc. (OTCBB:BOCX - News) announces results for lung cancer detection using its proprietary Serum-RECAF(TM) blood test. The results confirm 90% sensitivity with 95% specificity*. The findings further substantiate the use of RECAF(TM) as a universal cancer marker with a potential market size of $2 billion per year for all cancers. The study included 32 lung cancer patients and 103 normal donors with statistical verification. Dr. Moro commented: "Lung cancer is a terrible disease. It kills more people than any other type of cancer and it kills in a terrible way, by asphyxiation. It is gut wrenching to realize that even thought this is a preventable disease, the number of new cases and deaths keeps increasing each year. It is well established that early diagnosis results in better prognosis and that is why it was so important to develop a sensitive lung cancer test that catches 90% of cases with only 5% of false positives. Moreover, there is no other blood test that can detect lung cancer at the present time. The ultimate benefit to society could be enormous." These results are consistent with those obtained for other types of cancer and strengthen the concept of using Serum-RECAF(TM) as a valid test for screening the general populations for cancer. Since lung cancer, as well as many other cancers, is difficult to detect, the overall value of the RECAF technology in human and market terms is significant. Dr. Moro further stated, "It is not well understood by the general public, that we have very few methods available to tell if a person has a cancer. In fact, for most cancers, there are no existing specific tests. This is why RECAF is such a valuable technology. Even if we could only detect one type of cancer, we would have a significant discovery, but the studies demonstrate that we obtain continued excellent results in many differing types of cancers and at very high detection values. We are very excited about our potential as a biotech company." About lung cancer: Lung cancer is now the most common form of cancer diagnosed in the United States and a major cause of death. Lung cancer accounts for 14% of all cancers and 28% of all cancer deaths. At present, more Americans die from lung cancer than from breast, prostate, and colorectal cancers combined. Lung cancer has surpassed breast cancer as the most common type of cancer in women. Smoking costs the United States approximately $97.2 billion each year in health-care costs and lost productivity. It is directly responsible for 87 percent of lung cancer cases and causes most cases of emphysema and chronic bronchitis. About BioCurex: BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging and therapeutics. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (OTCBB:BOCX - News), visit our website at www.biocurex.com. Note: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. # Sensitivity is the number of true cancers picked by the test. Specificity is the percentage of normal samples that are negative with the test. Since 100% specificity is usually unattainable in biological systems, sensitivity is measured at an accepted specificity value of 95%. Contact: BioCurex, Inc. Ricardo Moro, 604-207-9150 Fax: 604-207-9165   We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 3525 Del Mar Heights Rd #334 San Diego, CA 92130 Unsubscribe Here D I S C L A I M E R : The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Click Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the company. Additionally, Some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services. Fees range from $3,000 to $5,000 per month. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. The editor, members of the editor's family, and/or entities with  which the editor is affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.